• Regorafenib Workflows for Angiogenesis Research

  2026-09-02

  Regorafenib (BAY 73-4506) supports integrated studies of kinase signaling, endothelial behavior, tumor-cell invasion, and melanoma mechanism. This practical guide connects dose-finding and migration assays with RRM2–ERK/E2F3 readouts for more interpretable cancer biology research.

• Sulfo-NHS-LC-Biotin Protocol and QC Guide

  2026-09-02

  Sulfo-NHS-LC-Biotin (SKU A8003) provides water-compatible, irreversible biotin labeling of accessible primary amines on proteins, peptides, and intact cell surfaces. It is suited to stable cell-surface protein biotinylation and streptavidin-based capture, but not to reversible modification or routine intracellular labeling.

• Sunitinib Workflows for RTK and RCC Research

  2026-09-01

  Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor for dissecting angiogenesis, tumor-cell survival, and resistance in advanced cancer models. This workflow-focused guide connects RTK pharmacology with metabolic rescue experiments, helping researchers distinguish direct pathway inhibition from glycolysis-driven treatment escape.

• ATRX Loss Increases Glioma Sensitivity to PDGFR Inhibitors

  2026-09-01

  The reference study shows that ATRX-deficient high-grade glioma cells are preferentially vulnerable to several receptor tyrosine kinase and PDGFR inhibitors, and that combining these agents with temozolomide can intensify cellular toxicity. Its main translational contribution is a genotype-aware framework for interpreting RTK inhibitor responses and designing glioma trials around ATRX status.

• NVP-BGJ398 Phosphate: FGFR1–3 Research Guide

  2026-08-31

  NVP-BGJ398 phosphate is a potent FGFR1–3 inhibitor for studying receptor-driven cancer and skeletal disease models. Its strongest evidence supports FGFR-altered cancer-cell assays and FGFR3-dependent SLC26A2 chondrodysplasia research, not clinical treatment.

• PR-619 Workflow for DUB Research

  2026-08-31

  PR-619 enables reversible, cell-permeable inhibition of multiple cysteine-dependent deubiquitinating enzymes without directly blocking proteasomal catalytic activity. This guide translates that distinction into practical workflows for ubiquitination pathway research, autophagy assays, cancer models, and carefully bounded neurodegeneration studies.

• Reactive Oxygen Species Assay Kit: Live-Cell ROS

  2026-08-30

  Learn how to use the Reactive Oxygen Species Assay Kit for controlled live-cell oxidative stress measurement, mechanism-focused treatment comparisons, and nanoparticle studies. A practical DCFH-DA workflow, control strategy, and troubleshooting guide helps distinguish a reproducible ROS-associated signal from assay interference.

• Salvianolic acid B: Designing Better Fibrosis Assays

  2026-08-29

  Salvianolic acid B, also known as Dan Shen Suan B, offers a useful way to study how LH2-dependent collagen maturation reshapes fibrotic lung models. This guide focuses on assay architecture, endpoint selection, compound handling, and the translational limits of interpreting antifibrotic responses.

• CRL3ARMC5 and Integrator Control RNA Pol II

  2026-08-28

  Cacioppo et al. identify CRL3ARMC5-mediated RNA polymerase II ubiquitylation and Integrator phosphatase activity as parallel quality-control pathways acting before productive elongation. The study shows that these mechanisms regulate both RNA Pol II abundance and transcriptional competence, providing a framework for interpreting early transcription defects and growth phenotypes after perturbation.

• miR-146a/b-5p–IRAK1–NF-κB in URSA

  2026-08-28

  A 2026 Journal of Molecular Recognition study integrates transcriptomic screening, trophoblast experiments, target validation, and a mouse model to define a miR-146a/b-5p–IRAK1–NF-κB regulatory axis in unexplained recurrent spontaneous abortion. The findings connect altered microRNA expression with trophoblast injury and pregnancy outcomes, while also outlining a testable framework for molecular validation of URSA-associated gene expression changes.

• CD36-Driven Lipid Signaling in AML Immune Escape

  2026-08-27

  This 2024 Cell Reports Medicine study identifies a non-canonical role for CD36 in acute myeloid leukemia: oxidized LDL sensing and palmitate transfer cooperate to activate innate immune signaling that suppresses T-cell activity. The work also shows that high-fat conditions and decitabine can intensify this immunosuppressive state, whereas lipid restriction with statins improves decitabine responses in experimental AML models.

• Cy5-UTP RNA Labeling: Workflow & Troubleshooting

  2026-08-27

  Cy5-UTP enables direct, orange-red visualization of RNA produced by T7 in vitro transcription, supporting FISH, probe QC, and multiplex expression assays without secondary staining. This practical guide connects labeling chemistry with workflow controls, LNP tracking considerations, and troubleshooting decisions that protect both fluorescence and RNA performance.

• KR-12 Human Antimicrobial Peptide Workflows

  2026-08-26

  KR-12 combines membrane-directed antimicrobial activity with anti-biofilm, LPS-neutralizing, and inflammation-focused research potential in a compact LL-37-derived sequence. This guide shows how to handle the TFA salt, build strain-aware assays, and control Cu(II)-dependent variables so formulation effects are not mistaken for biology.

• Ranolazine Workflows for Ischemia and Liver Assays

  2026-08-26

  Ranolazine supports distinct cardiac and hepatic workflows by combining late sodium current inhibition with metabolic substrate modulation. This guide translates those properties into practical assay design, while clearly separating established cardiac and liver applications from exploratory HBV–TBK1 research.

• Sulfaphenazole, Perfusion, and Pressure Injury Repair

  2026-08-25

  Turner and colleagues show that sulfaphenazole can reduce pressure- and thermal-injury severity in an ischemia–reperfusion model, with rapid restoration of tissue perfusion as a central response. The work links vascular protection to improved wound closure, tissue strength, reduced hypoxia, and lower inflammatory and fibrotic remodeling, while also identifying important limits to translation beyond the animal model.

7929 records 1/529 page Next 12345 下5页 Last page